tACS Treatment for Cognitive Impairments in Methamphetamine Addicts
Launched by BEIJING HUILONGGUAN HOSPITAL · Mar 2, 2024
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a treatment called transcranial alternating current stimulation (tACS) on people who have cognitive impairments due to methamphetamine use. The goal is to understand how methamphetamine affects brain function and to see if tACS can help improve thinking and memory skills in these patients. Researchers are currently looking for participants aged 18 to 65 who have a specific diagnosis of methamphetamine use disorder and do not have any other drug use, serious health issues, or mental illnesses.
If you or someone you know is eligible and decides to participate, you can expect to undergo some assessments to evaluate cognitive function and possibly receive the tACS treatment. This non-invasive treatment involves using a device that delivers a mild electrical current to the scalp, which aims to enhance brain activity. Participating in this trial could help you gain a better understanding of the impact of methamphetamine on your cognitive abilities and explore a potential new way to improve them.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis diagnosis of methamphetamine use disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
- • None of participants had mixed use of other drugs
- • None of participants had physical disability
- • None of participants had acute physical or mental illness, hallucinations, acute withdrawal symptoms
- • None of participants were receiving any medical treatment
- Exclusion Criteria:
- • Intracranial hypertension
- • Cranial defects
- • Tumors
- • Serious physical illnesses (e.g., cardiovascular, liver, kidney, gastrointestinal disorders)
- • Infectious diseases
- • Immune system disorders
About Beijing Huilongguan Hospital
Beijing Huilongguan Hospital is a leading medical institution in China, dedicated to providing advanced healthcare services and pioneering research in clinical medicine. With a strong emphasis on mental health and comprehensive patient care, the hospital is at the forefront of innovative treatment methodologies and clinical trials. As a sponsor of clinical research, Beijing Huilongguan Hospital collaborates with renowned experts and utilizes state-of-the-art facilities to facilitate the development of effective therapeutic interventions, contributing to the global body of medical knowledge and improving patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mianyang, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported